Magic
mushroom compound at least as good as antidepressant in UK study
Send a link to a friend
[April 15, 2021]
By Kate Kelland
LONDON (Reuters) - Psilocybin, the
psychedelic active compound in magic mushrooms, may be at least as
effective as a leading antidepressant drug and could help more patients
into remission from severe depression, a small study by British
scientists has found.
|
The findings, in the first-of-a-kind head-to-head comparison of
psilocybin therapy and the antidepressant escitalopram, suggests the
psychoactive ingredient has promise as a potential mental health
treatment, the researchers said.
"Remission rates were twice as high in the psilocybin group than the
escitalopram group," Robin Carhart-Harris, who designed and led the
study as head of the centre for psychedelic research at Imperial
College London, told a briefing.
"One of the most important aspects of this work is that people can
clearly see the promise of properly delivered psilocybin therapy by
viewing it compared with a more familiar, established treatment," he
said. "Psilocybin performed very favourably in this head-to-head."
Depression is one of the leading causes of ill health worldwide, and
existing treatments are often ineffective or have adverse side
effects that lead patients to stop taking them.
Carhart-Harris warned that while these findings - published in the
New England Journal of Medicine - were encouraging, patients with
depression should not try to self-medicate with magic mushrooms.
"That would be an error of judgment," he said.
The research involved 59 patients with moderate to severe depression
who got either a high dose of psilocybin and a placebo, or
escitalopram plus a dose of psilocybin so low as to be classed as
non-active and unlikely to have an effect.
This design was aimed at ensuring the two arms of the trial were as
alike as possible for those taking part.
Treatment response, defined as a reduction of at least 50% in
depression scores from baseline, was seen in 70% of people in the
psilocybin group and 48% in the escitalopram group.
[to top of second column] |
Results also showed that
remission of symptoms – measured as a score of 0
to 5 at week six – was seen in 57% of the
psilocybin group compared with 28% in the
escitalopram group. Carhart-Harris
said participants' reports suggested the psilocybin had a more
"fundamental" effect than antidepressants.
"I think it's getting more at the root causes of suffering," he
said. "There's a kind of epistemic quality to the treatment, a
revelatory quality, where people report feeling that they understand
more fully why they're depressed."
The Imperial team, co-led by David Nutt, a professor of
neuropsychopharmacology, has been exploring the potential of
psilocybin for many years.
In 2016 they published a small study showing psilocybin could help
ease a severe condition known as treatment-resistant depression.
The latest study was conducted under specific controlled conditions
with two therapists and a regulated dose formulated in laboratory
conditions, Nutt told the briefing, and taking magic mushrooms
without such safeguards could be dangerous.
(Reporting by Kate Kelland, editing by Mike Collett-White)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|